DIACORDON
Acute Coronary Syndrome (Heart Attack)
Development/CommercialActive
Key Facts
Indication
Acute Coronary Syndrome (Heart Attack)
Phase
Development/Commercial
Status
Active
Company
About Diagenics
Diagenics is a diagnostics company leveraging a proprietary biomarker platform to create rapid tests for emergency and critical care settings. Its product portfolio targets large markets in gynecology (preeclampsia), neurology (stroke), and cardiology (heart attack), with an additional commercial line in virology (COVID-19 antigen tests). Founded in 2005 and headquartered in Luxembourg with operational offices in Germany, the company positions itself as a pioneer in improving diagnostic speed and accuracy to influence patient outcomes.
View full company profileTherapeutic Areas
Other Acute Coronary Syndrome (Heart Attack) Drugs
| Drug | Company | Phase |
|---|---|---|
| GLS409 | Zata Pharmaceuticals | Pre-clinical |